Workflow
Biotech investment model
icon
Search documents
Ligand Announces 2025 Investor Day in New York City
Globenewswire· 2025-06-11 11:00
Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3] Upcoming Investor Day - Ligand Pharmaceuticals will host an Investor Day in New York City on December 9, 2025, at 10 a.m. Eastern Time [1] - The event will feature presentations from Ligand's senior management team discussing the company's strategy, investment activity, royalty portfolio, and long-term financial outlook [2] - A live webcast of the event will be available on Ligand's Investor Relations website, with a detailed agenda and dial-in information to be provided closer to the event [2] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [3] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [3] - The NITRICIL™ platform allows for tunable dosing and adjustable drug release profiles, targeting a broad range of indications [3] Partnerships and Alliances - Ligand has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]